Key Points
- Neve Stephen La, Accuray's CEO, bought 20,000 shares on Nov. 19 at an average price of $0.97 (total ~$19,400), a purchase disclosed in an SEC filing that raised their direct stake from zero to 20,000 shares (reported as an "∞" increase).
- Accuray shares trade at about $0.97 with a market cap near $109.49 million, a negative P/E, and the company reported quarterly EPS of ($0.18) that missed estimates despite revenue of $93.94M; analysts are mixed (average rating "Hold" with a $4.00 target).
Accuray Incorporated (NASDAQ:ARAY - Get Free Report) CEO Neve Stephen La bought 20,000 shares of Accuray stock in a transaction dated Wednesday, November 19th. The stock was purchased at an average price of $0.97 per share, with a total value of $19,400.00. Following the purchase, the chief executive officer directly owned 20,000 shares in the company, valued at approximately $19,400. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Accuray Stock Performance
Shares of Accuray stock traded up $0.04 on Thursday, reaching $0.97. 290,281 shares of the stock were exchanged, compared to its average volume of 819,554. The firm has a market capitalization of $109.49 million, a PE ratio of -47.70 and a beta of 1.39. Accuray Incorporated has a 1-year low of $0.91 and a 1-year high of $2.95. The business has a fifty day moving average price of $1.52 and a two-hundred day moving average price of $1.46. The company has a current ratio of 1.65, a quick ratio of 0.92 and a debt-to-equity ratio of 1.53.
Accuray (NASDAQ:ARAY - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.13). Accuray had a negative net margin of 0.35% and a negative return on equity of 4.92%. The business had revenue of $93.94 million during the quarter, compared to analysts' expectations of $91.34 million. Accuray has set its FY 2026 guidance at EPS. As a group, research analysts anticipate that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Accuray
Hedge funds and other institutional investors have recently modified their holdings of the company. Nuveen LLC acquired a new position in Accuray in the first quarter valued at $609,000. Hsbc Holdings PLC increased its stake in shares of Accuray by 15.4% during the 1st quarter. Hsbc Holdings PLC now owns 122,654 shares of the medical equipment provider's stock valued at $221,000 after acquiring an additional 16,389 shares during the last quarter. CSM Advisors LLC purchased a new position in shares of Accuray during the 2nd quarter worth about $527,000. Williams & Novak LLC lifted its holdings in shares of Accuray by 25.5% during the 2nd quarter. Williams & Novak LLC now owns 68,970 shares of the medical equipment provider's stock worth $94,000 after acquiring an additional 14,000 shares during the period. Finally, Armistice Capital LLC boosted its position in shares of Accuray by 105.2% in the first quarter. Armistice Capital LLC now owns 2,536,000 shares of the medical equipment provider's stock worth $4,539,000 after acquiring an additional 1,300,000 shares during the last quarter. 64.08% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts recently commented on ARAY shares. BTIG Research decreased their price objective on shares of Accuray from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, November 6th. Wall Street Zen lowered Accuray from a "hold" rating to a "sell" rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Accuray in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Accuray currently has an average rating of "Hold" and an average target price of $4.00.
Get Our Latest Report on Accuray
Accuray Company Profile
(
Get Free Report)
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
